Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTM2 | P28161 | 1/20 | 0.76 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 6/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | MYC | P01106 | 4/20 | 0.53 |
| ▸ | MAX | P61244 | 1/20 | 0.53 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | MIF | P14174 | 1/20 | 0.52 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.52 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15515612 | 1.00 | GSTM2 (0.76) | GSTM2HRH3MEN1KMT2AUSP2 | |
| SCHEMBL31320442 | 1.00 | GSTM2 (0.76) | GSTM2HRH3MEN1KMT2AUSP2 | |
| SCHEMBL285019 | 1.00 | GSTM2 (0.76) | GSTM2HRH3MEN1KMT2AUSP2 | |
| SCHEMBL15516469 | 1.00 | GSTM2 (0.76) | GSTM2HRH3MEN1KMT2AUSP2 | |
| SCHEMBL592618 | 1.00 | GSTM2 (0.76) | GSTM2HRH3MEN1KMT2AUSP2 | |
| SCHEMBL14617994 | 0.95 | GSTM2 (0.72) | GSTM2HRH3MEN1KMT2AUSP2 | |
| SCHEMBL30892505 | 0.91 | GSTM2 (0.76) | GSTM2HRH3MEN1KMT2AUSP2 | |
| SCHEMBL30892506 | 0.91 | GSTM2 (0.76) | GSTM2HRH3MEN1KMT2AUSP2 | |
| SCHEMBL17525024 | 0.90 | GSTM2 (0.67) | GSTM2HRH3MEN1KMT2AUSP2 | |
| SCHEMBL13524165 | 0.89 | GSTM2 (0.74) | GSTM2HRH3MEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 615 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| EP-4601623-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2025-08-20 | — | — | EP | claimed |
| CN-113454099-B | Detection of colonography in vivo using near infrared peptides targeting over-expression of cMET | 密歇根大学董事会 | 2025-05-27 | — | — | CN | claimed |
| EP-3497452-B1 | DIAGNOSIS, PREVENTION, AND/OR TREATMENT OF AUTOIMMUNE DISEASES | IMMUNOWORK LLC (US) | 2025-03-05 | — | — | EP | claimed |
| EP-3624846-B1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY INCLUDING A COMBINATION OF NICOTINIC ACID AND TRYOPTOPHAN | BHAMIS RES LABORATORY PVT LTD (IN) | 2024-08-07 | — | — | EP | claimed |
| WO-2024079738-A1 | ORAL POLYPEPTIDE FORMULATIONS | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | WO | claimed |
| WO-2024079739-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | WO | claimed |
| US-20240115702-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-11 | — | — | US | claimed |
| EP-4323007-A1 | POLYPEPTIDE FORMULATIONS | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-02-21 | — | — | EP | claimed |
| CN-117460536-A | Polypeptide formulations | 巴米研究实验室私人有限公司 | 2024-01-26 | — | — | CN | claimed |
| EP-1807103-A2 | MODULATORS OF RETINOL-RETINOL BINDING PROTEIN (RBP)-TRANSTHYRETIN (TTR) COMPLEX FORMATION | Sirion Therapeutics, Inc. (US) | 2007-07-18 | — | — | EP | claimed |
| US-20070098684-A9 | Methods of reducing aggregation of IL-1ra | RAIBEKAS ANDREI | 2007-05-03 | — | — | US | claimed |
| US-20070099235-A1 | Method for designing surfaces | BIO-LAYER PTY LIMITED (AU) | 2007-05-03 | — | — | US | claimed |
| EP-1700244-A1 | A METHOD FOR DESIGNING SURFACES | Bio-Layer Pty Limited (AU) | 2006-09-13 | — | — | EP | claimed |
| WO-2006052860-A2 | MODULATORS OF RETINOL-RETINOL BINDING PROTEIN (RBP)-TRANSTHYRETIN (TTR) COMPLEX FORMATION | SIRION THERAPEUTICS, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| US-20060094063-A1 | Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formation | SYTERA, INC. (US) | 2006-05-04 | — | — | US | claimed |
| US-20050282752-A1 | Reducing aggregation of an aggregating interleukin-1 receptor antagonist (IL-1ra); rheumatoid arthritis | SWEDISH ORPHAN BIOVITRUM AB (PUBL) (SE) | 2005-12-22 | — | — | US | claimed |
| US-20050271618-A1 | Methods of reducing aggregation of IL-1ra | SWEDISH ORPHAN BIOVITRUM AB (PUBL) (SE) | 2005-12-08 | — | — | US | claimed |
| WO-2005057462-A1 | A METHOD FOR DESIGNING SURFACES | BIO-LAYER PTY LIMITED (AU) | 2005-06-23 | — | — | WO | claimed |
| US-20030035755-A1 | Organic electroluminescence (OEL)-based biochips | HELIX TECHNOLOGY INC. (TW) | 2003-02-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115702-A1 | HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY | ALB, TTR, MAX | GSTM2 3945/4885HRH3 4685/4885MEN1 1928/4885 |
| US-20050271618-A1 | Methods of reducing aggregation of IL-1ra | IL1RN, IL1A, IL1B | GSTM2 2752/4885HRH3 3393/4885MEN1 4501/4885 |
| US-20070098684-A9 | Methods of reducing aggregation of IL-1ra | IL1RN, IL1A, IL1B | GSTM2 2752/4885HRH3 3393/4885MEN1 4501/4885 |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | GLP1R, TTR, IAPP | GSTM2 4387/4885HRH3 3285/4885MEN1 1288/4885 |
| US-20060094063-A1 | Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formation | RBP1, TTR, RBP4 | GSTM2 3042/4885HRH3 4219/4885MEN1 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.